An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee

Trial Profile

An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Osteoarthritis
  • Focus Pharmacokinetics
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 04 May 2017 According to a Flexion Therapeutics media release, data from this trial has been presented at the Osteoarthritis Research Society International (OARSI) 2017 World Congress.
    • 28 Apr 2017 According to a Flexion Therapeutics media release data from this trial will be presented at the Osteoarthritis Research Society International (OARSI) 2017 World Congress.
    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top